Completed
Phase 1 Study of Quizartinib
NCT02675478
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +6 more
- Locations
-
- Tokyo, Japan
Clinical trial condition
Relapsed AML
Explore clinical trials studying Relapsed AML. Study availability and eligibility vary by location and protocol.
2 public trials
0 recruiting studies
Relapsed AML trial results
Active, Not Recruiting
CART123 + Ruxolitinib in Relapsed/Refractory AML
NCT06768476
- Conditions
- Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
- Locations
-
- University of Pennsylvania Philadelphia, Pennsylvania, United States